Epstein-Barr virus transmission from a blood donor to an organ transplant recipient with recovery of the same virus strain from the recipient's blood and oropharynx.
A previous study (Savoie et al, Blood 83:2715, 1994) identified eight transplant patients who acquired Epstein-Barr virus (EBV) infection during the peritransplant period. Three of these patients subsequently developed B-cell lymphoproliferative disease within 4 months of transplantation. Among these, there was a 16-year-old liver transplant patient who was negative for EBV at the time of transplant and who received an EBV-negative organ. After transplant, this patient was transfused with 9 U of packed red blood cells. Eight of the donors were EBV-positive and one was EBV-negative. We succeeded in obtaining spontaneous lymphoblastoid cell lines (LCLs) from the blood of three of these donors, one of whom also yielded a cord-blood line established with his throat-wash EBV. Blood from a fourth donor did not yield an LCL, but his throat washing did have transforming activity when inoculated onto cord-blood leukocytes. We initially could establish spontaneous LCLs only from the recipient's blood. However, a throat-wash sample taken 11 weeks later did show transforming activity. The recipient was shown to have acquired the EBV infection from one of eight EBV-seropositive blood donors. Analysis of fragment length polymorphisms after polymerase chain reaction amplification of the EBV BamHI-K fragment was used to establish strain identity. Western blot analysis for existence of size polymorphisms in three classes of Epstein-Barr nuclear antigens (EBNA-1, EBNA-2, and EBNA-3) confirmed the DNA results. It is noteworthy that the blood donor responsible for transmitting his EBV strain to the recipient had experienced clinical infectious mononucleosis 15 months before donating blood. Our results may, thus, indicate a requirement for leukodepletion of blood destined for immunosuppressed EBV-negative patients. Finally, blood donors with a recent history of infectious mononucleosis should probably be identified so that their blood is not given to EBV-negative transplant patients.
Alfieri
C
C
Department of Microbiology and Immunology, Sainte-Justine Hospital (Pediatric Research Center), Montréal, Quebec, Canada.
Tanner
J
J
Carpentier
L
L
Perpête
C
C
Savoie
A
A
Paradis
K
K
Delage
G
G
Joncas
J
J
D000293:Adolescent; D000956:Antigens, Viral / Q000235:genetics / Q000302:isolation & purification; D001782:Blood Donors; D016358:Contact Tracing; D004279:DNA, Viral / Q000235:genetics / Q000302:isolation & purification; D004268:DNA-Binding Proteins / Q000235:genetics / Q000302:isolation & purification; D019309:Epstein-Barr Virus Nuclear Antigens; D005260:Female; D005953:Glycogen Storage Disease Type I / Q000601:surgery; D006566:Herpesviridae Infections / Q000635:transmission* / Q000821:virology; D004854:Herpesvirus 4, Human / Q000235:genetics / Q000302:isolation & purification; D006801:Humans; D016031:Liver Transplantation; D009960:Oropharynx / Q000821:virology*; D011110:Polymorphism, Genetic; D011183:Postoperative Complications / Q000821:virology*; D012463:Saliva / Q000821:virology; D065227:Transfusion Reaction; D014412:Tumor Virus Infections / Q000635:transmission* / Q000821:virology; D014766:Viremia / Q000821:virology*; D014775:Virus Activation
D000956:Antigens, Viral; D004279:DNA, Viral; D004268:DNA-Binding Proteins; D019309:Epstein-Barr Virus Nuclear Antigens